Compare BRZE & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRZE | IOVA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 968.6M |
| IPO Year | 2021 | N/A |
| Metric | BRZE | IOVA |
|---|---|---|
| Price | $33.27 | $2.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 12 |
| Target Price | ★ $44.70 | $10.36 |
| AVG Volume (30 Days) | 2.1M | ★ 9.8M |
| Earning Date | 12-09-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $693,412,000.00 | $250,425,000.00 |
| Revenue This Year | $23.36 | $60.94 |
| Revenue Next Year | $17.31 | $60.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 22.95 | ★ 175.62 |
| 52 Week Low | $23.91 | $1.64 |
| 52 Week High | $48.33 | $8.56 |
| Indicator | BRZE | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 63.64 | 46.56 |
| Support Level | $27.76 | $2.18 |
| Resistance Level | $37.33 | $2.32 |
| Average True Range (ATR) | 1.27 | 0.12 |
| MACD | 0.65 | -0.01 |
| Stochastic Oscillator | 59.70 | 18.11 |
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates majority of its revenue from the United States.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.